Abstract
Background: Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice, which brings great economic burden to patients. This study evaluated the economics of the new antiarrhythmic drug dronedarone and provides suggestions for allocation of health resources.Methods: Amiodarone was selected as the control group, and the Markov model of AF was established using nine states. The total cost and quality-adjusted life year (QALY) of dronedarone and amiodarone groups were calculated and compared. The incremental cost effectiveness ratio (ICER) value was calculated and compared with the willingness to pay (WTP) and the sensitivity analyses was conducted.Results: For China's healthcare system, the ICER of the dronedarone group compared with the amiodarone group was RMB 81,741 Yuan/QALY, which is lower than the current recommended WTP (3 times GDP per capita). Sensitivity analyses showed that the model was robust, and the drug price of dronedarone significantly impacted the results.Conclusions: Compared with amiodarone, dronedarone is more economical in the Chinese healthcare system. However, due to the lack of data on the Chinese population for some parameters, the model needs further improvement and discussion. Real-world studies on the effects of dronedarone on Chinese patients with AF would be beneficial.
Highlights
Atrial fibrillation (AF) is one of the most common arrhythmias in the clinic
The decrease of the HF: amiodarone vs. dronedarone (HR) value of amiodarone vs. dronedarone in patients with stroke, the utility of AF and the discount of cost may cause the increase of incremental costeffectiveness ratio (ICER), making dronedarone an uneconomical regimen
This study was the first to evaluate the economics of dronedarone and amiodarone in Chinese patients with AF, which is of significance for the selection of drugs for sinus rhythm maintenance in Chinese patients with AF and provides evidence of resource allocation for government departments
Summary
Atrial fibrillation (AF) is one of the most common arrhythmias in the clinic. The lifetime risk of AF in people over the age of 14 years is 26% for men and 23% for women [2]. According to an epidemiological survey of 726,451 people in 31 provinces and regions in China in 2017, the standardized incidence of AF among people over 40 years old in China was 2.31%, and with increasing age, the prevalence in women (2.72%) was significantly higher than that in men (1.90%) [3]. Cost-Effectiveness of Dronedarone and Amiodarone of life (QoL) and increase their financial burden. Atrial fibrillation (AF) is one of the most common arrhythmias in clinical practice, which brings great economic burden to patients. This study evaluated the economics of the new antiarrhythmic drug dronedarone and provides suggestions for allocation of health resources
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call